New drug duo aims to control rare blood cancer
NCT ID NCT07199296
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 30 times
Summary
This study tests a combination of two drugs (orelabrutinib and rituximab) in people newly diagnosed with a slow-growing type of mantle cell lymphoma. Some participants may also receive a stem cell transplant using their own cells. The goal is to see how well the treatment shrinks or eliminates the cancer and how long the effects last. About 45 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA (MCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital
RECRUITINGShanghai, 200025, China
Conditions
Explore the condition pages connected to this study.